

BOOK BY 7 AUGUST AND SAVE £400
BOOK BY 29 AUGUST AND SAVE £200
BOOK BY 26 SEPTEMBER AND SAVE £100

SAE MEDIA
GROUP

SAE Media Group Proudly Presents The 4th Annual Conference...

Transdermal and Microneedle Drug Delivery

Advancing the Next Generation of
Drug Delivery Systems Beyond the Needle

Hilton London Kensington, UK

10 - 11
NOV
2025

HIGHLIGHTS FOR 2025:

- **Engage** the evolving transdermal and microneedle market with expert insights into emerging trends and innovations.
- **Learn** about novel drug delivery applications, from biologics to small molecules, and their clinical impact.
- **Uncover** best practices, regulatory considerations, and technical advancements in microarray patch technology.
- **Dive** into the latest developments in transdermal and microneedle-based vaccines, optimizing accessibility and efficacy.
- **Network** with pharma, biotech, device developers, and regulatory experts driving next-generation drug delivery innovations.



SAE Media Group Pharma
@SAEMGPharma
#SAETransdermal

www.transdermal-microneedle-delivery.co.uk
Register online or call +44 (0) 870 9090 711

LETTER FROM THE CHAIRS:

Dear Colleagues,

It is with great pleasure that we invite you to SAE's Transdermal and Microneedle Drug Delivery Conference, taking place on the 10th – 11th November 2025 in London.

As part of SAE's leading series of drug delivery conferences, this year's event will once again bring together leading experts from big pharma, innovative biotech, regulatory bodies, and key associations, all united in advancing the field of transdermal and microneedle drug delivery.

Building on the successes of previous years, the 2025 agenda will highlight the latest breakthroughs in transdermal drug delivery, alongside an exciting exploration of next-generation microneedle technologies.

We will delve into crucial developments, including the growing real-world applications of microneedle systems for vaccine delivery, emerging trends positioning transdermal drug delivery as a transformative therapeutic tool, pioneering research in microarray patches, microneedle-driven diagnostics, and the latest regulatory insights shaping the future of this evolving landscape.

We are confident that this conference will provide invaluable insights, foster meaningful collaborations, and drive forward innovation in transdermal and microneedle drug delivery. We look forward to seeing you in London this November for an engaging and thought-provoking event.

Yours Sincerely,



Sanjiv Sharma,
Senior Lecturer in Infectious Diseases and
Antimicrobial Resistance, **University of Liverpool**

08.00 Registration & Coffee

09.00 Chair's Opening Remarks

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and
Antimicrobial Resistance, **University of Liverpool**

AN OUTLOOK ON THE TRANSDERMAL AND MICRONEEDLE LANDSCAPE

09.10 OPENING ADDRESS

Microneedles for Long-Acting Drug Therapy

- Developing microneedles for optimised drug release control for the delivery of long acting therapies
- Utilising microneedle technology as a minimally invasive and user-friendly delivery method, and to enhance adherence to long-acting treatments
- Opportunities in expanding therapeutic applications, from vaccines to chronic disease management
- Future directions: discussing advances in materials, formulation, preclinical models and regulatory pathways to drive widespread adoption

James Birchall, Deputy Head, School of Pharmacy and
Pharmaceutical Sciences, College of Biomedical and
Life Sciences, **Cardiff University**



09.50 Navigating Regulatory Challenges in Transdermal Drug Delivery

- Reviewing the impact of MDR and Article 117 and understanding how the requirements affect transdermal drug delivery systems
- Delving into manufacturer responsibilities and ensuring compliance with quality, safety, and efficacy standards for transdermal products
- Efficiently handling changes in drug formulations and patch technology
- Strategies for demonstrating regulatory compliance and clinical effectiveness

Arabe Ahmed, Medicinal Technical Specialist, **BSI**

10.30 Morning Coffee

NOVEL TRANSDERMAL AND MICRONEEDLE THERAPEUTICS AND APPLICATIONS

11.00 Delivery of cancer immunotherapeutics using microneedle technologies to achieve contextual T cell Priming

- Cancer immunotherapeutic strategies
 - Nanoparticle and microneedle technologies for delivery of antigens to skin resident dendritic cell populations
 - Early clinical data treating pancreatic cancer
- Brian Pfister,** Vice President, **Glyden Pharma**

11.40 Session Reserved for Sponsor

12.10 Beyond Delivery: Harnessing Transdermal Diagnostics for Precision Medicine

- Exploring how transdermal diagnostic technologies complement transdermal drug delivery for real-time monitoring
- Innovations in microneedle-based and wearable biosensors for continuous biomarker tracking
- How transdermal diagnostics can enable adaptive drug dosing and improve therapeutic outcomes
- Addressing scalability, regulatory hurdles, and commercialization pathways for transdermal diagnostics

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and
Antimicrobial Resistance, **University of Liverpool**



12.50 Networking Lunch

14.00 Intradermal Delivery of Anti-IL-17A/F VHH Antibody for Plaque Psoriasis Treatment

- Exploring targeted intradermal administration and approaches for enhancing drug delivery efficiency for localised psoriasis treatment
- Reviewing advantages of VHH Antibody fragments including improved stability, penetration, and therapeutic potential
- Clinical and translational considerations, highlight strategies for optimising formulation and delivery for patient outcomes
- Outlook on future applications and development - expanding microneedle and transdermal technology for dermatological treatments

Amir Reichman, CEO, Executive and Member of the Board of
Directors, **Scinai Immunotherapeutics**

14.40 Session Reserved for Sponsor

15.10 Development of a testosterone patch for women using novel S-PURE adhesive technology

- S-PURE cross-linked adhesive has superior characteristics for drug delivery patches
- Clinical need for testosterone patch for post-menopausal women
- Formulation development for optimised transdermal API delivery
- Phase 1 pharmacokinetics of testosterone patch

John Burt, CEO, **Medherant**

15.50 Afternoon Tea

16.20 Revolutionising Treatment Through Advanced Microneedle Systems

- Enhancing patient comfort with minimally invasive and self-administered treatments
- Programmable Microfluidics: On-demand, adaptive drug release with precision dosing control for personalised therapy
- Integrating biosensors for real-time drug monitoring, feedback systems, and remote diagnostics
- Implementing sustainable design with biodegradable, recyclable microneedle platforms

Conor O'Mahony, Principle Researcher, **Tyndall National Institute**

FIRESIDE CHAT

17.00 The Future of Transdermal & Microneedle Therapeutics

- Key takeaways on therapeutic opportunities and real-world applications, highlighting how transdermal and microneedle technologies are shaping the future of drug delivery, patient accessibility, and treatment effectiveness
- Navigating Development & Commercialisation Challenges – Addressing regulatory hurdles, manufacturing scalability, and market adoption and potential strategic approaches for overcoming these obstacles
- Looking ahead to emerging technologies, investment priorities, and industry growth – Exploring cutting-edge innovations, the evolving role of microneedle and transdermal delivery systems, and the key investment trends that will drive future advancements in biopharma and healthcare applications

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and
Antimicrobial Resistance, **University of Liverpool**

James Birchall, Deputy Head, School of Pharmacy and
Pharmaceutical Sciences, College of Biomedical and Life
Sciences, **Cardiff University**

John Burt, CEO, **Medherant**

Amir Reichman, CEO, Executive and Member of the Board
of Directors, **Scinai Immunotherapeutics**



17.40 Chair's Closing Remarks and Close of Day One

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and
Antimicrobial Resistance, **University of Liverpool**

Interested in Sponsorship?



SAE Media Group offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to compliment your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry.

Should you wish to join the conference, please call:

Ash Khan | Sponsorship Sales Manager T: +44 (0) 20 7827 6110 E: ash.khan@saemediagroup.com

[Secure your ticket here](#)

08.30 Registration & Coffee

09.00 Chair's Opening Remarks

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, **University of Liverpool**

ADVANCING MAP DEVELOPMENT AND MANUFACTURING

OPENING ADDRESS

09.10 **Advancing Vaccine Delivery: Microarray Patch Technology in Support of CEPI's 100-Days Mission**



- CEPI aims to prepare the world for epidemics and pandemics, by accelerating vaccine development and enabling equitable access
- Vaccine patches play an important role in this mission, because of their distribution and delivery advantages
- Microarray patch platform technology development is essential for pandemic preparedness, to be able to use these patches in a rapid response situation

Renske Hesselink, Director M&S&C Innovations, **CEPI**

09.50 **Microneedle Patch Technology: From Pre-clinical Success to First-in-Human**

- Translating pre-clinical insights into early human studies
- Meeting key safety & regulatory milestones
- Pathways for scale-up and commercial adoption

Muhammet Avcil, Managing Director, **Imperial BioScience**

10.30 Morning Coffee

11.00 **Priority implementation research to inform integration of MAPs into immunization programmes**

- Key areas of study needed to facilitate the seamless adoption of microneedle array patches (MAPs) in immunization programmes
- Addressing regulatory, logistical, and operational barriers while leveraging MAP advantages for broader vaccine coverage
- Leveraging real-world data and pilot studies to inform policy decisions and optimize MAP distribution
- Exploring global partnerships, funding opportunities, and next steps to accelerate MAP adoption

Mateusz Hasso-Agopsowicz, Technical Officer, **WHO**

11.40 Session Reserved for Sponsor

12.10 **Microneedles in drug products: Payer value drivers**

- Unmet need
- Payer value drivers
- Clinical evidence: Case study DerMap in onychomycosis
- Strategic recommendations

Waleed Faisal, CEO, **ArrayPatch Ltd**

12.50 Networking Lunch

UTILISING TRANSDERMAL AND MICRONEEDLE TECHNOLOGY FOR VACCINE DELIVERY

14.00 **Strategically Developing Vaccine Delivery Technologies for Global Health**

- Insight into Micron's microarray technology
- Reviewing key packaging and technology considerations for finding successful alternatives to administer vaccines than traditional routes
- Discussing the key needs from partnerships in the space for effective technology development and outcomes

Steve Damon, Chief Executive Officer, **Micron Biomedical**

14.40 Session Reserved for Sponsor

15.10 Afternoon Tea

15.40 **Transforming the vaccine landscape with the development of needle-free vaccine patches**

- Exploring HD-MAP technology for vaccine administration
- Learnings from recent usability and accessibility studies
- Advantages of needle-free vaccine delivery

Senior Representative, Vaxxas

PANEL DISCUSSION

16.20 **Advancing the potential of microarray patches (MAPs) for effective vaccine and therapeutic delivery**



- Reviewing the current landscape of MAP technology and latest developments in the field
- Outlining challenges in MAP development including cost of goods, cold chain and regulatory uncertainties, and potential approaches to overcome these
- Exploring the use of AI in programs and the potential benefits
- Examples of current collaboration and partnerships, and how these can be utilised to drive future success in the development, deployment and use of MAPs

Panel Moderator:

Ajoy Chakrabarti, Portfolio and Platform Lead, **Gates Foundation***

Panelist:

Steve Damon, Chief Executive Officer, **Micron Biomedical**

Senior Representative, Vaxxas

17.00 **Chair's Closing Remarks and Close of Day Two**

Sanjiv Sharma, Senior Lecturer in Infectious Diseases and Antimicrobial Resistance, **University of Liverpool**

* Subject to Final Confirmation

UPCOMING EVENTS

Wearable Injectors and Connected Devices USA

8 September - 9 September 2025
Courtyard By Marriott Boston
Downtown, USA

Pre-Filled Syringes and Injectable Drug Devices Europe

13 January - 15 January 2026
Royal Garden Hotel,
London, United Kingdom

AI in Drug Discovery

9 March - 10 March 2026
Hilton London Kensington,
United Kingdom

OFFICIAL MEDIA PARTNERS



MARKETING OPPORTUNITIES

Want to know how you can get involved? Interested in promoting your services to this market?
Contact Alessandra De Maria | Senior Marketing Executive | T: +44 (0) 20 7827 6124 | E: alessandra.demaria@saemediagroup.com

Alternatively call +44 (0)870 9090 711

3 WAYS TO REGISTER

Online at
www.transdermal-microneedle-delivery.comEmail your booking form to
marketingteam@saemediagroup.comPHONE on
+44 (0) 870 9090 711

Our Reference P-451

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

If you would like to continue to receive email updates about our events, please tick ☐

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel:

Mobile:

Switchboard:

Signature: Date:

I agree to be bound by SAE Media Group Terms and Conditions of Booking

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel:

VENUE Hilton London Kensington, 179-199 Holland Park Ave, London W11 4UL

☐ For any queries, call us on +44 (0) 870 9090 711,
email: events@saemediagroup.com

BOOKING SUMMARY

CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)

Price

VAT

IN-PERSON ATTENDANCE

☐ Standard Price		£2298.00	+ VAT
☐ Register and pay by 7 August 2025	Save £400.00	£1898.00	+ VAT
☐ Register and pay by 29 August 2025	Save £200.00	£2098.00	+ VAT
☐ Register and pay by 26 September 2025	Save £100.00	£2198.00	+ VAT

PROMOTIONAL LITERATURE DISTRIBUTION

☐ Distribution of your company's promotional literature to all conference attendees	£999.00	+ VAT
--	---------	-------

As an added benefit of attending this conference, check here to receive a free subscription to Medical Design Briefs, the leading new technology magazine for bio-medical professionals. Choose either: ☐ Print (U.S. only) ☐ Digital

The conference fee includes on-demand access to the Document Portal. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 7 working days post-conference.

DOCUMENTATION

I cannot attend but would like to Purchase access to the following Document Portal

Price

☐ Access to the conference documentation on the Document Portal	£699.00	+ VAT
--	---------	-------

VAT

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here

PAYMENT

Payment must be made to **SMi Group Ltd**, and received before the event, by one of the following methods **quoting reference P-451 and the delegate's name**. Bookings made within 7 days of the event require payment on booking, methods of payment:

☐ UK BACS	Sort Code 300009, Account 00936418
☐ Wire Transfer	Lloyds TSB Bank plc, 70-71 Cheapside, London, EC2V 6EN Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18
☐ Credit Card	A payment link will be sent with your invoice.

Terms and Conditions of Booking

Payment: Our payment terms are as follows: if booking 16 days or more before the conference, payment should be made within 14 days of date of invoice. If booking 15 days or less before the conference, payment is due on receipt of invoice and must be received no later than the last working day prior to the event start date. In the event, that the customer has not paid by the last working day before the event, we reserve the right to obtain card details for payment to be taken for the full invoice amount or as a guarantee of payment. Access to the Document Portal will not be given until payment is received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not 'share' a place at an event. Please make separate bookings for each delegate.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee, providing that cancellation is made in writing and received 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings, we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund of your payment but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. By registering for this event, you are providing us with some personal details, including an email address. Smi Group Ltd Trading as SAE Media Group will process that information as described in our privacy policy <https://www.smgconferences.com/privacy-legals/privacy-policy/> Part of the value of our events is in the networking and relationship building opportunities. To support this, we may facilitate professional introductions on-site at our events.